Laboratorio Reig Jofre S.A.
ISIN: ES0165359029 | Ticker: RJF | LEI: 9598003MRMJHA81QJF20
Country: Spain
Founded in 1929 in Barcelona, Spain, REIG JOFRE is a pharmaceutical company listed on the Spanish Stock Exchange market, under the ticker RJF, dedicated to the research, development, manufacture and marketing of pharmaceutical products and food supplements.
REIG JOFRE structures its product development activity in three business areas:
- Pharmaceutical Technologies specialized in the development and manufacture of sterile and lyophilized injectable pharmaceutical products, as well as antibiotics derived from penicillin.
- Specialty Pharmacare focused on the research, development, manufacture and commercialization of specialties in the areas of dermatology and osteoarticular, mainly.
- Consumer Healthcare with the line of food supplements marketed under the Forté Pharma brand mostly in France, Belgium, Spain and Portugal, as well as other OTC products.
1929
Served areaWorldwide
Headcount1,100
HeadquartersCl/ Gran Capita 10, 8970 Barcelona – Spain
| Line item in (eur) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | 313,615,000.00 | 317,151,000.00 | 324,976,000.00 | 321,191,000.00 |
| Noncurrent Assets | N/A | 217,193,000.00 | 216,424,000.00 | 216,140,000.00 | 208,890,000.00 |
| Property Plant And Equipment | N/A | 83,917,000.00 | 85,284,000.00 | 92,387,000.00 | 93,192,000.00 |
| Goodwill | N/A | 29,730,000.00 | 29,972,000.00 | 29,843,000.00 | 28,972,000.00 |
| Intangible Assets Other Than Goodwill | N/A | N/A | 82,832,000.00 | 77,727,000.00 | 70,893,000.00 |
| Other Intangible Assets | N/A | 85,879,000.00 | 82,832,000.00 | N/A | N/A |
| Investments In Associates Accounted For Using Equity Method | N/A | 1,220,000.00 | 1,308,000.00 | 1,948,000.00 | 3,541,000.00 |
| Deferred Tax Assets | N/A | 14,585,000.00 | 14,876,000.00 | 12,642,000.00 | 10,680,000.00 |
| Other Noncurrent Financial Assets | N/A | 658,000.00 | 938,000.00 | 414,000.00 | 410,000.00 |
| Current Assets | N/A | 96,422,000.00 | 100,727,000.00 | 108,836,000.00 | 112,301,000.00 |
| Inventories | N/A | 38,353,000.00 | 40,450,000.00 | 47,682,000.00 | 48,190,000.00 |
| Trade And Other Current Receivables | N/A | 40,542,000.00 | 42,621,000.00 | 44,419,000.00 | 49,811,000.00 |
| Current Tax Assets Current | N/A | 4,144,000.00 | 4,616,000.00 | 6,016,000.00 | 5,106,000.00 |
| Other Current Financial Assets | N/A | 924,000.00 | 801,000.00 | 973,000.00 | 444,000.00 |
| Cash and cash equivalents | N/A | 10,171,000.00 | 11,591,000.00 | 5,065,000.00 | 6,454,000.00 |
| Other Current Assets | N/A | 2,288,000.00 | 648,000.00 | 4,681,000.00 | 2,296,000.00 |
| Equity And Liabilities | N/A | 313,615,000.00 | 317,151,000.00 | 324,976,000.00 | 321,191,000.00 |
| Equity | 149,741,000.00 | 178,138,000.00 | 184,478,000.00 | 188,514,000.00 | 194,553,000.00 |
| Issued Capital | N/A | 38,031,000.00 | 38,401,000.00 | 38,716,000.00 | 39,211,000.00 |
| Share Premium | N/A | 19,000,000.00 | 19,000,000.00 | 19,000,000.00 | 19,000,000.00 |
| Treasury Shares | N/A | 1,138,000.00 | 1,708,000.00 | 2,404,000.00 | 2,815,000.00 |
| Other Reserves | N/A | 118,559,000.00 | 123,505,000.00 | 128,819,000.00 | 133,445,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 178,200,000.00 | 184,546,000.00 | 188,594,000.00 | 194,634,000.00 |
| Noncontrolling Interests | N/A | -62,000.00 | -68,000.00 | -80,000.00 | -81,000.00 |
| Noncurrent Liabilities | N/A | 66,906,000.00 | 54,862,000.00 | 61,548,000.00 | 51,038,000.00 |
| Noncurrent Government Grants | N/A | 1,729,000.00 | 2,438,000.00 | 3,065,000.00 | 3,695,000.00 |
| Deferred Tax Liabilities | N/A | 3,103,000.00 | 3,318,000.00 | 3,053,000.00 | 2,799,000.00 |
| Other Noncurrent Liabilities | N/A | 13,000,000.00 | 0.00 | N/A | N/A |
| Noncurrent Portion Of Noncurrent Loans Received | N/A | 8,893,000.00 | 26,930,000.00 | 34,670,000.00 | 25,438,000.00 |
| Current Liabilities | N/A | 68,571,000.00 | 77,811,000.00 | 74,914,000.00 | 75,600,000.00 |
| Current Provisions | N/A | 82,000.00 | 25,000.00 | 15,000.00 | 45,000.00 |
| Trade And Other Current Payables | N/A | 36,241,000.00 | 40,608,000.00 | 41,897,000.00 | 43,965,000.00 |
| Current Contract Liabilities | N/A | N/A | 1,429,000.00 | 8,031,000.00 | 3,549,000.00 |
| Current Tax Liabilities Current | N/A | N/A | N/A | 3,955,000.00 | 3,070,000.00 |
| Other Current Liabilities | N/A | 15,098,000.00 | 15,120,000.00 | 2,150,000.00 | 527,000.00 |
| Current Loans Received And Current Portion Of Noncurrent Loans Received | N/A | 6,518,000.00 | 9,210,000.00 | 12,727,000.00 | 18,516,000.00 |
| Line item in (eur) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue | 200,207,000.00 | 230,079,000.00 | 236,231,000.00 | 271,150,000.00 |
| Changes In Inventories Of Finished Goods And Work In Progress | -1,515,000.00 | -2,369,000.00 | 4,827,000.00 | -1,043,000.00 |
| Other Work Performed By Entity And Capitalised | 5,625,000.00 | 3,682,000.00 | 3,640,000.00 | 3,063,000.00 |
| Raw Materials And Consumables Used | 75,426,000.00 | 92,128,000.00 | 86,659,000.00 | 114,138,000.00 |
| Employee Benefits Expense | 57,132,000.00 | 66,434,000.00 | 64,185,000.00 | 70,472,000.00 |
| Depreciation And Amortisation Expense | 13,148,000.00 | 16,983,000.00 | 18,047,000.00 | 21,063,000.00 |
| Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 243,000.00 | 361,000.00 | 436,000.00 | 973,000.00 |
| Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 243,000.00 | 361,000.00 | 436,000.00 | 973,000.00 |
| Profit Loss From Operating Activities | 6,323,000.00 | 9,228,000.00 | 8,863,000.00 | 8,532,000.00 |
| Finance Income | 71,000.00 | 32,000.00 | 50,000.00 | 101,000.00 |
| Finance Costs | 1,048,000.00 | 990,000.00 | 910,000.00 | 996,000.00 |
| Profit Loss Before Tax | 5,303,000.00 | 6,426,000.00 | 5,793,000.00 | 8,764,000.00 |
| Income Tax Expense Continuing Operations | 364,000.00 | 760,000.00 | 713,000.00 | 658,000.00 |
| Profit Loss From Continuing Operations | 4,939,000.00 | 5,666,000.00 | 5,080,000.00 | 8,106,000.00 |
| Profit (loss) | 4,939,000.00 | 5,666,000.00 | 5,080,000.00 | 8,106,000.00 |
| Profit Loss Attributable To Owners Of Parent | 4,942,000.00 | 5,672,000.00 | 5,092,000.00 | 8,107,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | N/A | -6,000.00 | -12,000.00 | -1,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | 4,939,000.00 | 5,666,000.00 | 5,080,000.00 | 8,106,000.00 |
| Adjustments For Finance Costs | N/A | 990,000.00 | 910,000.00 | 996,000.00 |
| Adjustments For Decrease Increase In Inventories | -4,101,000.00 | -3,001,000.00 | -7,108,000.00 | -1,058,000.00 |
| Adjustments For Increase Decrease In Other Operating Payables | 6,322,000.00 | 1,450,000.00 | N/A | N/A |
| Adjustments For Depreciation And Amortisation Expense | 13,148,000.00 | 16,983,000.00 | 18,047,000.00 | 21,063,000.00 |
| Adjustments For Provisions | 93,000.00 | -8,000.00 | -10,000.00 | 30,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | 156,000.00 | -68,000.00 | 363,000.00 | -58,000.00 |
| Other Adjustments To Reconcile Profit Loss | 0.00 | 0.00 | -3,967,000.00 | -9,744,000.00 |
| Interest Paid Classified As Operating Activities | 1,048,000.00 | 990,000.00 | 883,000.00 | 1,041,000.00 |
| Interest Received Classified As Operating Activities | 71,000.00 | 32,000.00 | 26,000.00 | 146,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | 1,325,000.00 | 1,639,000.00 | 913,000.00 | 883,000.00 |
| Cash Flows From Used In Operating Activities | 11,679,000.00 | 18,572,000.00 | 14,497,000.00 | 16,147,000.00 |
| Other Cash Payments To Acquire Interests In Joint Ventures Classified As Investing Activities | 20,000,000.00 | 15,000,000.00 | 15,000,000.00 | 2,000,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | 0.00 | -82,000.00 | 114,000.00 | 113,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 5,847,000.00 | 11,745,000.00 | 19,225,000.00 | 10,946,000.00 |
| Proceeds From Sales Of Intangible Assets Classified As Investing Activities | 26,000.00 | 513,000.00 | 0.00 | 47,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | 25,298,000.00 | 191,000.00 | 537,000.00 | 453,000.00 |
| Proceeds From Other Longterm Assets Classified As Investing Activities | 1,965,000.00 | 186,000.00 | 234,000.00 | 707,000.00 |
| Purchase Of Other Longterm Assets Classified As Investing Activities | 1,267,000.00 | 449,000.00 | 282,000.00 | 184,000.00 |
| Cash Flows From Used In Investing Activities | -50,421,000.00 | -26,768,000.00 | -34,696,000.00 | -12,716,000.00 |
| Proceeds From Issuing Shares | 24,000,000.00 | 0.00 | 0.00 | 0.00 |
| Proceeds From Issuing Other Equity Instruments | 0.00 | 0.00 | N/A | N/A |
| Payments To Acquire Or Redeem Entitys Shares | 238,000.00 | 628,000.00 | 753,000.00 | 363,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | 21,885,000.00 | 19,352,000.00 | 22,856,000.00 | 13,779,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | 4,644,000.00 | 11,735,000.00 | 15,155,000.00 | 16,837,000.00 |
| Proceeds From Government Grants Classified As Financing Activities | 0.00 | 2,062,000.00 | 178,000.00 | 390,000.00 |
| Dividends Paid Classified As Financing Activities | 359,000.00 | 88,000.00 | 55,000.00 | 53,000.00 |
| Other Inflows Outflows Of Cash Classified As Financing Activities | 0.00 | 1,429,000.00 | 6,602,000.00 | 1,530,000.00 |
| Cash Flows From Used In Financing Activities | 40,644,000.00 | 9,616,000.00 | 13,673,000.00 | -2,042,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | 1,902,000.00 | 1,420,000.00 | -6,526,000.00 | 1,389,000.00 |
| Cash and cash equivalents | 10,171,000.00 | 11,591,000.00 | 5,065,000.00 | 6,454,000.00 |
Please note that some sums might not add up.
ES0165359029
LEI9598003MRMJHA81QJF20
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.